5O'Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging studv of mometasone furoate drt powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allery, Asthma Immunol,2001 ;86:397 - 404.
6Bousquet J,D'Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry. powder inhaler to budesonide Turbuhaler. Eur Respir J,2000; 16:808- 816.
7Derendorf H, Daley-Yates PT, Pierre LN, et al. Bioavailability and metabolism of mometasone furoate: pharmacology, versus methodology. J Clin Pharmacol, 2002 ; 42 : 383 - 387.
8Bousquet J. Cantini L. Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclonletasone dipropionate ( BDP Modulite).Respir Med, 2002 ; 96 : S 17 - 27.
9Leach CL,Davidson PJ, Hasselquist BE, et al. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon flutleasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest,2002; 122:510- 516.
10Daley-Yates PT, Price AC, Sisson JR, et al. Beclonaethasone dipropionate: absolute bloavailability, pharmacokinetics and metabolism following intravenous.oral,intranasal and inhaled administration in man. Br J Clin Pharmacol,2001 ;51:400 - 409.